Patents by Inventor George Sheppard

George Sheppard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bromodomain Inhibitors
    Publication number: 20220017511
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: February 24, 2021
    Publication date: January 20, 2022
    Applicant: AbbVie Inc.
    Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
  • PRIMARY CARBOXAMIDES AS BTK INHIBITORS
    Publication number: 20210179556
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 17, 2021
    Inventors: Dominique Bonafoux, Heather Michele Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep Kaur Somal, Jennifer Van Camp, Stacy Anne Van Epps, Anil Vasudevan, Grier Allan Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • Bromodomain Inhibitors
    Publication number: 20210130346
    Abstract: Compounds of formula (I), wherein R1, R2, R3, R5, R6, R7, A1, A2, A3, A4, X1, and X2 have any of the values defined in the specification and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS are provided. Pharmaceutical compositions comprising of compounds of formula (I) are also provided.
    Type: Application
    Filed: April 14, 2017
    Publication date: May 6, 2021
    Applicant: AbbVie Inc.
    Inventors: David Hardee, Jason Brewer, Lisa Hasvold, Dachun Liu, Keith McDaniel, Michael Schrimpf, George Sheppard
  • Bromodomain Inhibitors
    Publication number: 20210047304
    Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: May 26, 2020
    Publication date: February 18, 2021
    Inventors: Marlon Cowart, Steven Fidanze, Lisa Hasvold, Dachun Liu, Keith McDaniel, John Pratt, George Sheppard, Le Wang
  • Bromodomain Inhibitors
    Publication number: 20200255426
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Applicant: AbbVie Inc.
    Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
  • Bromodomain inhibitors
    Patent number: 10633379
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: April 28, 2020
    Assignee: AbbVie Inc.
    Inventors: Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, George Sheppard, Le Wang
  • Bromodomain Inhibitors
    Publication number: 20190382383
    Abstract: Provided herein are compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: October 14, 2016
    Publication date: December 19, 2019
    Inventors: Marlon Cowart, Steven Fidanze, Lisa Hasvold, Dachun Liu, Keith McDaniel, John Pratt, George Sheppard, Le Wang
  • Bromodomain Inhibitors
    Publication number: 20190345153
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: April 14, 2017
    Publication date: November 14, 2019
    Applicant: AbbVie Inc.
    Inventors: Steven D. Fidanze, Lisa A. Hasvold, Dachun Liu, Keith F. McDaniel, John Pratt, Michael Schrimpf, George Sheppard, Le Wang, Bing Li
  • PRIMARY CARBOXAMIDES AS BTK INHIBITORS
    Publication number: 20190284135
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 19, 2019
    Inventors: Dominique Bonafoux, Heather Michele Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep Kaur Somal, Jennifer Van Camp, Stacy Anne Van Epps, Anil Vasudevan, Grier Allan Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • Bromodomain Inhibitors
    Publication number: 20190084981
    Abstract: The present invention provides for compounds of formula (I) wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: November 16, 2018
    Publication date: March 21, 2019
    Inventors: Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James Holms, Dachun Liu, William McClellan, Keith McDaniel, Jasmina Marjanovic, George Sheppard, Le Wang
  • Bromodomain inhibitors
    Patent number: 10131657
    Abstract: The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: November 20, 2018
    Assignee: AbbVie Inc.
    Inventors: Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James Holms, Dachun Liu, William McClellan, Keith McDaniel, Jasmina Marjanovic, George Sheppard, Le Wang
  • Bromodomain inhibitors
    Patent number: 9957263
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 1, 2018
    Assignee: AbbVie Inc.
    Inventors: Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James Holms, Dachun Liu, William McClellan, Keith McDaniel, Jasmina Marjanovic, George Sheppard, Le Wang
  • PRIMARY CARBOXAMIDES AS BTK INHIBITORS
    Publication number: 20170174624
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: January 5, 2017
    Publication date: June 22, 2017
    Applicant: AbbVie Inc.
    Inventors: Dominique Bonafoux, Heather M. Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep K. Somal, Jennifer Van Camp, Stacy A. Van Epps, Anil Vasudevan, Grier A. Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • Primary carboxamides as BTK inhibitors
    Patent number: 9567339
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: February 14, 2017
    Assignee: AbbVie Inc.
    Inventors: Dominique Bonafoux, Heather M. Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep K. Somal, Jennifer Van Camp, Stacy A. Van Epps, Anil Vasudevan, Grier A. Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • Bromodomain Inhibitors
    Publication number: 20160272630
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.
    Type: Application
    Filed: June 27, 2014
    Publication date: September 22, 2016
    Applicant: AbbVie Inc.
    Inventors: Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James Holms, Dachun Liu, William McClellan, Keith McDaniel, Jasmina Marjanovic, George Sheppard, Le Wang
  • Bromodomain Inhibitors
    Publication number: 20160185769
    Abstract: The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: May 13, 2014
    Publication date: June 30, 2016
    Applicant: Abbvie Inc.
    Inventors: Yujia Dai, Steven D. Fidanze, Lisa Hasvold, James Holms, Dachun Liu, William McClellan, Keith McDaniel, Jasmina Marjanovic, George Sheppard, Le Wang
  • PRIMARY CARBOXAMIDES AS BTK INHIBITORS
    Publication number: 20150005279
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: June 26, 2014
    Publication date: January 1, 2015
    Applicant: ABBVIE INC.
    Inventors: Dominique Bonafoux, Heather M. Davis, Kristine E. Frank, Michael M. Friedman, J. Martin Herold, Michael Z. Hoemann, Raymond Huntley, Augustine Osuma, George Sheppard, Gagandeep K. Somal, Jennifer Van Camp, Stacy A. Van Epps, Anil Vasudevan, Grier A. Wallace, Lu Wang, Lu Wang, Zhi Wang, Noel S. Wilson, Xiangdong Xu
  • PROTEIN KINASE INHIBITORS
    Publication number: 20070203143
    Abstract: Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.
    Type: Application
    Filed: December 28, 2006
    Publication date: August 30, 2007
    Inventors: George Sheppard, Gary Wang, Fabio Palazzo, Randy Bell, Robert Mantei, Jieyi Wang, Robert Hubbard, Megumi Kawai, Scott Erickson, Nwe BaMaung, Steve Fidanze
  • 3-substituted indole antiproliferative angiogenesis inhibitors
    Publication number: 20020091148
    Abstract: 3-Substituted indole carbohydrazides having the formula 1
    Type: Application
    Filed: September 14, 2001
    Publication date: July 11, 2002
    Inventors: Nwe Y. BaMaung, Richard A. Craig, Megumi Kawai, Jieyi Wang, Yujia Dai, Yan Guo, George Sheppard, Mary K. Verzal, Anil Vasudevan, Michael Michaelides